|
||||
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi |
||||
|
|
|||
1. Identity of the issuer or the underlying issuer |
Oxford Biomedica Plc |
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
X |
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
An event changing the breakdown of voting rights |
|
|||
Other (please specify): |
|
|
||
3. Full name of person(s) subject to the |
Prudential plc group of companies |
|||
4. Full name of shareholder(s) |
Prudential plc M&G Group Limited M&G Limited M&G Investment Management Limited M&G Securities Limited
|
|||
5. Date of the transaction and date on |
05 August 2015 |
|||
6. Date on which issuer notified: |
06 August 2015 |
|||
7. Threshold(s) that is/are crossed or |
18% - 17% |
|||
8. Notified details: |
||||||||||||||||
A: Voting rights attached to shares viii, ix |
||||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
||||||||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
||||||||||||
GB0006648157 |
463,083,605 |
463,083,605 |
462,983,605 |
462,983,605 |
0 |
17.99% |
0 |
|||||||||
|
||||||||||||||||
B: Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||||||||
|
|
|
|
|
||||||||||||
|
||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|||||||||||
|
|
|
|
|
Nominal |
Delta |
||||||||||
|
|
|||||||||||||||
|
||||||||||||||||
Total (A+B+C) |
||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||
462,983,605 |
17.99% |
|||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
||
Prudential plc (parent Company) - 462,983,605 (17.99%) M&G Group Limited (wholly owned subsidiary of Prudential plc) - 462,983,605 (17.99%) M&G Limited (wholly owned subsidiary of M&G Group Limited) - 462,983,605 (17.99%) M&G Investment Management Limited (wholly owned subsidiary of M&G Limited) - 462,983,605 (17.99%) M&G Securities Limited (wholly owned subsidiary of M&G Limited) - 439,485,985 (17.08%)
|
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
N/A |
|
11. Number of voting rights proxy holder will cease |
N/A |
|
12. Date on which proxy holder will cease to hold |
N/A |
|
|
||
|
|
|
14. Contact name: |
Tim Watts, Oxford BioMedica PLC |
|
15. Contact telephone number: |
01865 783000 |
|